EL7 Research · Public Offerings
20 November 2026 · After the first trading session closed on 19 November · Final prospectus
Anthropic priced its shares at $83, raising $81.34 billion in the largest IPO on record by base deal size. The stock then opened on Nasdaq at $111.50 and closed at $97.17. We explain the deal’s three figures, how the first day unfolded minute by minute, when the comparison with SpaceX will be settled, what SpaceX’s first five months tell us, what analysts expect, our three scenarios and the dates that will shape the stock’s course.
Anthropic began trading on Nasdaq on Thursday, 19 November, under the ticker ANT. The previous evening, it priced its shares at $83, above the announced range of $70 to $78, and increased the number of shares on offer from 825 million to 980 million. The initial public offering (IPO), the company’s first sale of shares to the public, raised $81.34 billion. That made it the largest base IPO on record, ahead of the $75 billion SpaceX raised in June. SpaceX increased its final proceeds to $85.7 billion after the banks exercised the overallotment option (Greenshoe) in full, using their right to buy additional shares at the offer price. The comparison of final proceeds remains open until Anthropic’s option exercise window closes around 18 December.
Almost the entire gain came in the first few minutes. The opening auction (Opening Cross), which matches buy and sell orders to set the opening price, established the first trade at 11:48 a.m. New York time. The stock opened at $111.50, 34.3% above the offer price. It then reached $115.10 before falling to $92.72 at around 1:18 p.m. and closing at $97.17. It ended its first day 17.07% above the offer price and 12.85% below the opening price. In the same session, the Nasdaq Composite fell 2.25% and the Dow Jones index dropped about 1,101 points.
A company’s equity market value (Market Capitalization) is its share price multiplied by its share count. At the close, it was about $1.3 trillion based on the shares in investors’ hands (Shares Outstanding), which totalled 13.22 billion. It was about $1.77 trillion using the share count after dilution (Fully Diluted Shares), which adds the shares the company could issue under existing rights to those already outstanding, for an estimated total of 18.2 billion shares. Revenue was $35.28 billion in the twelve months through September and $16.96 billion in the third quarter alone. The analysts’ target prices (Price Targets) we verified range from $92 at Morningstar to $150 at Needham.
Our assessment is that the stock’s first-day close was very close to the weighted value of about $102 a share across our three first-year scenarios. The first-day price thus broadly reflected our base case (Baseline Scenario), the most likely path underlying our forecasts. The price did not reflect the upside scenario. Around mid-December, we are watching for the overallotment option to expire and for the underwriting banks to begin publishing research on the stock. We are also watching for the first tranche of locked-up shares to become eligible for sale on 15 December, followed by the company’s first annual results since listing.
A free account gives you 4 full research papers every month. Or subscribe to EL7 Pro for full access to more than 300 papers.
$700 per year · or $99 per month